How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?

FAQ Library published on July 18, 2016
Download Transcript Download Audio
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Hi and welcome to Managing Myeloma. My name is Dr. Sagar Lonial, and I am a Professor at the Winship Cancer Institute of Emory University in Atlanta, Georgia. Another great question that I am often asked is, “How do we determine which patients will benefit the most from treatment with daratumumab and elotuzumab?” And I think some of that is going to be driven by a lot of the data that is emerging, both at the ASCO meeting in 2016 as well as at ASH, and in the coming years. Because what we know about monoclonal antibodies from many other clinical trials and many other clinical settings is that they seem to be additive to pretty much any other therapy that is available. So, I think what we are going to see is the addition of monoclonal antibodies to induction therapy, to consolidation therapy, and to maintenance therapy, and I think understanding which drug may be better suited for each of these different phases of treatment will depend on the clinical data. So far, we have just a few small trials. There is emerging data on randomized phase 3s, both with elotuzumab and daratumumab, that is coming in an induction therapy setting in combination with bortezomib and in combination with lenalidomide in larger phase 3 trials, and these will be critical to better answering those questions. Thank you for your attention and please tune into ManagingMyeloma.com for additional FAQs.

Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017
Related Items by Author
Practice-changing trials to watch for in 2018
Sagar Lonial, MD, FACP
FAQ Library published on January 24, 2018
A key educational message from ASH 2017
Sagar Lonial, MD, FACP
FAQ Library published on January 12, 2018
Is there a role for Bcl-2 directed treatment for patients with translocation 11;14?
Sagar Lonial, MD, FACP
FAQ Library published on October 11, 2017
How will the new IMWG definition of active multiple myeloma impact clinical practice?
Sagar Lonial, MD, FACP
FAQ Library published on August 18, 2016
What is the role of SPEP, UPEP and immunofixation in managing multiple myeloma patients?
Sagar Lonial, MD, FACP
FAQ Library published on July 6, 2016
Is BD or KD a standard of care in relapsed/refractory multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on June 15, 2016
Which is the best indicator of improved outcomes in multiple myeloma: sCR, CR, IFCR or MCR?
Sagar Lonial, MD, FACP
FAQ Library published on May 10, 2016
What new classes of therapy are emerging for multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on March 10, 2016
How does one define high-risk smoldering or asymptomatic multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on November 6, 2014
What are the mechanisms of renal complications in patients with multiple myeloma?
Sagar Lonial, MD, FACP
FAQ Library published on March 15, 2011 in Comorbidities/SEs